Targeting Tumor Glycans for Cancer Therapy: Successes, Limitations, and Perspectives.
Targeting Tumor Glycans for Cancer Therapy: Successes, Limitations, and Perspectives.
复制标题
DOI：
10.3390/cancers14030645
复制
发表时间：
2022-01-27
期刊：
影响因子：
5.2
通讯作者：
Osinaga E
中科院分区：
文献类型：
--
作者：
Berois N;Pittini A;Osinaga E
异常糖基化是许多癌症的共同特征，并且其在肿瘤发展和生物学中起关键作用。癌症进展可以通过由糖基化控制的几种生理病理过程来调节，例如细胞-细胞粘附、细胞-基质相互作用、上皮-间充质转化、肿瘤增殖、侵袭和转移。异常糖基化的不同机制导致肿瘤相关碳水化合物抗原（TACA）的形成，其适用于选择性癌症靶向，以及新的抗肿瘤免疫治疗方法。本文综述了以TACA为靶点的肿瘤免疫治疗策略，分析了TACA的分子和细胞机制以及临床肿瘤学的最新方法。异常糖基化是癌症的标志，可导致影响肿瘤行为的变化。聚糖可以作为新型临床生物标志物开发的来源，为治疗干预提供一组特定靶标。异常糖基化的不同机制导致形成适合选择性癌症靶向治疗的肿瘤相关碳水化合物抗原（TACA）。最佳表征的TACA是截短的O-聚糖（Tn、TF和唾液酸-Tn抗原）、神经节苷脂（GD 2、GD 3、GM 2、GM 3、岩藻糖基-GM 1）、球系列聚糖（Globo-H、SSEA-3、SSEA-4）、刘易斯抗原和聚唾液酸。在这篇综述中，我们分析了针对TACA的癌症免疫治疗策略，包括不同抗体的开发，疫苗的生产和CAR-T细胞的产生。一些方法已被批准用于临床使用，例如抗GD 2抗体。此外，在针对不同TACA的抗肿瘤机制方面，我们显示了选定临床试验的结果，考虑到由于用于癌症控制的技术的最新发展而开辟的视野。
Aberrant glycosylation is a common feature of many cancers, and it plays crucial roles in tumor development and biology. Cancer progression can be regulated by several physiopathological processes controlled by glycosylation, such as cell–cell adhesion, cell–matrix interaction, epithelial-to-mesenchymal transition, tumor proliferation, invasion, and metastasis. Different mechanisms of aberrant glycosylation lead to the formation of tumor-associated carbohydrate antigens (TACAs), which are suitable for selective cancer targeting, as well as novel antitumor immunotherapy approaches. This review summarizes the strategies developed in cancer immunotherapy targeting TACAs, analyzing molecular and cellular mechanisms and state-of-the-art methods in clinical oncology. Aberrant glycosylation is a hallmark of cancer and can lead to changes that influence tumor behavior. Glycans can serve as a source of novel clinical biomarker developments, providing a set of specific targets for therapeutic intervention. Different mechanisms of aberrant glycosylation lead to the formation of tumor-associated carbohydrate antigens (TACAs) suitable for selective cancer-targeting therapy. The best characterized TACAs are truncated O-glycans (Tn, TF, and sialyl-Tn antigens), gangliosides (GD2, GD3, GM2, GM3, fucosyl-GM1), globo-serie glycans (Globo-H, SSEA-3, SSEA-4), Lewis antigens, and polysialic acid. In this review, we analyze strategies for cancer immunotherapy targeting TACAs, including different antibody developments, the production of vaccines, and the generation of CAR-T cells. Some approaches have been approved for clinical use, such as anti-GD2 antibodies. Moreover, in terms of the antitumor mechanisms against different TACAs, we show results of selected clinical trials, considering the horizons that have opened up as a result of recent developments in technologies used for cancer control.
登录
查看更多内容
DOI：
10.1155/2015/132326
发表时间：
2015
期刊：
Pathology research international
影响因子：
--
作者：
Blanco R;Domínguez E;Morales O;Blanco D;Martínez D;Rengifo CE;Viada C;Cedeño M;Rengifo E;Carr A
通讯作者：
Carr A
影响因子：
3.8
作者：
Bassaganas, Sonia;Allende, Helena;Peracaula, Rosa
通讯作者：
Peracaula, Rosa
影响因子：
--
作者：
Kurtenkov O;Izotova J;Klaamas K;Sergeyev B
通讯作者：
Sergeyev B
DOI：
10.1155/2013/602417
发表时间：
2013
期刊：
Journal of biomarkers
影响因子：
--
作者：
Blanco R;Quintana Y;Blanco D;Cedeño M;Rengifo CE;Frómeta M;Ríos M;Rengifo E;Carr A
通讯作者：
Carr A
影响因子：
--
作者：
Berriel E;Russo S;Monin L;Festari MF;Berois N;Fernández G;Freire T;Osinaga E
通讯作者：
Osinaga E